Bioventix PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVXP.L research report →
Companywww.bioventix.com
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.
- CEO
- Peter John Harrison
- IPO
- 2014
- Employees
- 17
- HQ
- Farnham, GB
Price Chart
Valuation
- Market Cap
- $86.99M
- P/E
- 11.70
- P/S
- 6.94
- P/B
- 7.88
- EV/EBITDA
- 8.56
- Div Yield
- 9.01%
Profitability
- Gross Margin
- 91.93%
- Op Margin
- 75.62%
- Net Margin
- 59.30%
- ROE
- 65.83%
- ROIC
- 66.47%
Growth & Income
- Revenue
- $13.12M · -3.61%
- Net Income
- $7.58M · -6.33%
- EPS
- $1.45 · -6.45%
- Op Income
- $9.90M
- FCF YoY
- -15.80%
Performance & Tape
- 52W High
- $3020.00
- 52W Low
- $1300.00
- 50D MA
- $1642.00
- 200D MA
- $1940.92
- Beta
- 0.56
- Avg Volume
- 11.87K
Get TickerSpark's AI analysis on BVXP.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BVXP.L Coverage
We haven't published any research on BVXP.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BVXP.L Report →